Key facts
- This page summarizes Steven H. Stein's Form 4 filing for INCYTE CORP (INCY).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 07 Nov 2025, 16:01.
Steven H. Stein - 05 Nov 2025 Form 4 Insider Report for INCYTE CORP (INCY)
- Reporting relationship
- EVP & Chief Medical Officer
- Issuer ticker
- INCY
- Reported as of
- 05 Nov 2025
- Net transaction value
- -$47,945
- SEC form
- 4
- Accepted by SEC
- 07 Nov 2025, 16:01:10 UTC
- Prior SEC filing
- 23 Jul 2025
- Next SEC filing
- 03 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Feeney, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven H. Stein filed Form 4 for INCYTE CORP (INCY) on 07 Nov 2025.
Change
- Previous filing in this sequence was filed on 23 Jul 2025.
- Current net transaction value: -$47,945.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001673776
Primary reporting owner
Stein Steven H
- Relationship
- EVP & Chief Medical Officer
- Address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON
- Signature
- /s/ Elizabeth Feeney, Attorney-In-Fact
- Signature date
- 07 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- $100,093
- Shares
- +1,194
- Change %
- +1.2%
- Price
- $83.83
- Shares after
- 104,080
- Date
- 05 Nov 2025
- Ownership
- Direct
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- $286,801
- Shares
- +2,995
- Change %
- +2.9%
- Price
- $95.76
- Shares after
- 107,075
- Date
- 05 Nov 2025
- Ownership
- Direct
INCY
transaction
Common Stock
Options Exercise
- Transaction value
- $99,973
- Shares
- +1,044
- Change %
- +0.98%
- Price
- $95.76
- Shares after
- 108,119
- Date
- 05 Nov 2025
- Ownership
- Direct
INCY
transaction
Common Stock
Sale
- Transaction value
- $534,813
- Shares
- -5,233
- Change %
- -4.8%
- Price
- $102.20
- Shares after
- 102,886
- Date
- 05 Nov 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INCY
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,194
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,194
- Exercise price
- $83.83
- Footnotes
- F2
INCY
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,995
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,995
- Exercise price
- $95.76
- Footnotes
- F3
INCY
transaction
Derivative
Incentive Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,044
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 05 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,044
- Exercise price
- $95.76
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
Footnote F2
Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Footnote F3
Beginning January 7, 2016, options become exercisable in full on January 7, 2020.